Why Cancer Vaccines Often Fail in BRCA1-Mutated Ovarian Cancer

Researchers from the lab of Prof. Lana E. Kandalaft, of the Swiss Medical Network and the University of Lausanne (UNIL), have uncovered an important mechanism explaining why some BRCA1-mutated ovarian cancers fail to respond to cancer vaccines—and how that resistance can be overcome.

Published in iScience, the study demonstrates that ovarian cancers carrying BRCA1 mutations are fundamentally different from those carrying BRCA2 mutations. Although BRCA1-mutated tumors are heavily infiltrated by immune cells, many of these T cells are already functionally exhausted, preventing therapeutic vaccines from generating a stronger antitumor response.

Using advanced preclinical models and spatial transcriptomics, the researchers found that dendritic cell vaccines effectively activated antitumor immunity and prolonged survival in BRCA2-deficient and BRCA-wild-type tumors, but not in BRCA1-deficient tumors. Importantly, combining the vaccine with PD-1 immune checkpoint blockade and PARP inhibition restored T-cell function, generated stronger tumor-specific immune responses, and produced durable tumor control.

These findings suggest that the major obstacle in BRCA1-mutated ovarian cancer is not a lack of immune cells but immune exhaustion. Reversing this exhaustion may unlock the full potential of therapeutic cancer vaccines.

Although these findings are preclinical and require validation in patients, they provide a strong rationale for future clinical trials combining cancer vaccines, PARP inhibitors, and immune checkpoint inhibitors for BRCA1-mutated ovarian cancer.